HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control

Karen Canfell, Jane J. Kim, Shalini Kulasingam, Johannes Berkhof, Ruanne Barnabas, Johannes A. Bogaards, Nicole Campos, Chloe Jennett, Monisha Sharma, Kate T. Simms, Megan A. Smith, Louiza S. Velentzis, Marc Brisson, Mark Jit

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Intense research activity in HPV modelling over this decade has prompted the development of additional guidelines to those for general modelling. A specific framework is required to address different policy questions and unique complexities of HPV modelling. HPV-FRAME is an initiative to develop a consensus statement and quality-based framework for epidemiologic and economic HPV models. Its development involved an established process. Reporting standards have been structured according to seven domains reflecting distinct policy questions in HPV and cancer prevention and categorised by relevance to a population or evaluation. Population-relevant domains are: 1) HPV vaccination in pre-adolescent and young adolescent individuals; 2) HPV vaccination in older individuals; 3) targeted vaccination in men who have sex with men; 4) considerations for individuals living with HIV and 5) considerations for low- and middle-income countries. Additional considerations applicable to specific evaluations are: 6) cervical screening or integrated cervical screening and HPV vaccination approaches and 7) alternative vaccine types and alternative dosing schedules. HPV-FRAME aims to promote the development of models in accordance with an explicit framework, to better enable target audiences to understand a model's strength and weaknesses in relation to a specific policy question and ultimately improve the model's contribution to informed decision-making.

Original languageEnglish (US)
Article number100184
JournalPapillomavirus Research
Volume8
DOIs
StatePublished - Dec 2019

Bibliographical note

Funding Information:
KC is co-principal investigator of an investigator-initiated trial of cytology and primary HPV screening in Australia (“Compass”), which is conducted and funded by the VCS Foundation, a government-funded health promotion charity. VCS has received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and Ventana USA. However neither KC, nor her institution on her behalf ( Cancer Council NSW ) has received direct or indirect funding from industry for Compass Australia or NZ or any other project. JB has received grants from the European Community during the conduct of the study and personal fees from GSK and Merck and non-financial support from DDL outside the submitted work. The fees from GSK and Merck were collected by the employer. JJK, SK, RB, JAB, NC, CJ, MS, KTS, MAS, LSV, MB and MJ have nothing to disclose.

Funding Information:
KC is co-principal investigator of an investigator-initiated trial of cytology and primary HPV screening in Australia (?Compass?), which is conducted and funded by the VCS Foundation, a government-funded health promotion charity. VCS has received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and Ventana USA. However neither KC, nor her institution on her behalf (Cancer Council NSW) has received direct or indirect funding from industry for Compass Australia or NZ or any other project. JB has received grants from the European Community during the conduct of the study and personal fees from GSK and Merck and non-financial support from DDL outside the submitted work. The fees from GSK and Merck were collected by the employer. JJK, SK, RB, JAB, NC, CJ, MS, KTS, MAS, LSV, MB and MJ have nothing to disclose.

Publisher Copyright:
© 2019 The Authors

Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.

Keywords

  • Cervical screening
  • Guidelines
  • Human papillomavirus
  • Modelling
  • Prevention
  • Vaccination

Fingerprint Dive into the research topics of 'HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control'. Together they form a unique fingerprint.

Cite this